about
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.Case based measles surveillance in Pune: evidence to guide current and future measles control and elimination efforts in India.Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.Group A streptococcal vaccines: paving a path for accelerated development.Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group.Two-dose schedules for human papillomavirus vaccine: Systematic review and meta-analysis.Ebola vaccine--an urgent international priority.A randomized, controlled trial of an aerosolized vaccine against measles.Comparing pneumococcal conjugate vaccine schedules in infancy.Ebola vaccination - Authors' reply.Changes in the primary outcome in Ebola vaccine trial--Authors' reply.Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.Guiding Vaccine Efficacy Trial Design During Public Health Emergencies: An interactive web-based decision support toolConsiderations for the design of vaccine efficacy trials during public health emergenciesQuestionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' replyAn online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-ToolData sharing for novel coronavirus (COVID-19)Disappearance of Myelinated Retinal Nerve Fibers after Central Retinal Artery Occlusion Reveals Nettleship Collaterals
P50
Q28051937-F581633A-BCA0-4FD0-9120-99EB5606C016Q33924959-06C9D445-0639-49B8-A261-C134A4026D6CQ34301475-05A98F41-5B5D-4B7E-9A34-A593D221680CQ34488529-8DB9DED1-62AC-4208-98CA-6D3F151CB57CQ37032973-76FCE2A1-D69E-4C4E-8909-60ABD1CE8E0BQ38100042-986ED5C2-C4B5-4A3D-AC58-979D53E92D94Q38170603-1BF32091-02C9-44F4-AA78-14FAA92CA0F8Q38813649-AF7FB532-1ED9-4C8A-8AA8-B7F45E080B53Q40188051-AA1868A6-23FF-4255-97B1-18576D326A5CQ41071279-444FDD40-0FFF-443D-8EE0-D8D54FF4F033Q44031699-D9669D69-F174-47CA-BBAD-27F34B339D01Q44101398-225F70D0-E7D4-4341-8B07-DB0104FA8201Q44102519-A479AA23-93DF-4181-8551-3866F8391A77Q44105902-51577A75-E377-49CF-8E52-F5679B3DEC30Q56489846-012003DB-CB8A-4066-8892-4602FAF3119FQ56830716-3844F11E-DF23-4240-8B95-399416BFF73CQ59350196-0425CA7B-A69C-4D88-AFAA-5E77CFBFAB92Q66679104-E1A2CC62-ECC1-4D1E-BC98-67093E301FBBQ87461301-918AC7E3-C405-4BDB-A75A-1A7E5C96B869Q88812947-5D86A7D0-42E1-48BC-859C-CEFD8400937E
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-9910-7999
@en
name
Ana Maria Henao-Restrepo
@ast
Ana Maria Henao-Restrepo
@en
Ana Maria Henao-Restrepo
@es
Ana Maria Henao-Restrepo
@nl
type
label
Ana Maria Henao-Restrepo
@ast
Ana Maria Henao-Restrepo
@en
Ana Maria Henao-Restrepo
@es
Ana Maria Henao-Restrepo
@nl
prefLabel
Ana Maria Henao-Restrepo
@ast
Ana Maria Henao-Restrepo
@en
Ana Maria Henao-Restrepo
@es
Ana Maria Henao-Restrepo
@nl
P106
P21
P31
P496
0000-0001-9910-7999